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Abstract
Background and aims
Pathogenic mutations in the Low Density Lipoprotein Receptor gene (LDLR) cause Familial
Hypercholesterolemia (FH), one of the most common genetic disorders with a prevalence
as high as 1 in 200 in some populations. FH is an autosomal dominant disorder of lipoprotein
metabolism characterized by high blood cholesterol levels, deposits of cholesterol in periph-
eral tissues such as tendon xanthomas and accelerated atherosclerosis. To date, 2500
LDLR variants have been identified in the LDLR gene; however, only a minority of them
have been experimentally characterized and proven to be pathogenic. Here we investigated
the role of Cys46 located in the first repeat of the LDL receptor binding domain in recognition
of apolipoproteins.
Methods
Activity of the p.(Cys46Gly) LDLR variant was assessed by immunoblotting and flow cytom-
etry in CHO-ldlA7 expressing the receptor variant. Affinity of p.(Cys46Gly) for LDL and
VLDL was determined by solid-phase immunoassays and in silico analysis was used to pre-
dict mutation effects.
Results and conclusion
Functional characterization of p.(Cys46Gly) LDLR variant showed impaired LDL and VLDL
binding and uptake activity. Consistent with this, solid-phase immunoassays showed the p.
(Cys46Gly) LDLR variant has decreased binding affinity for apolipoproteins. These results
indicate the important role of Cys46 in LDL receptor activity and highlight the role of LR1 in
LDLr activity modulation. This study reinforces the significance of in vitro functional charac-
terization of LDL receptor activity in developing an accurate approach to FH genetic
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diagnosis. This is of particular importance because it enables clinicians to tailor personalized
treatments for patients’ mutation profile.
Introduction
Familial Hypercholesterolemia is an autosomal dominant disorder causing premature coro-
nary heart disease (CHD) [1] characterized by high blood cholesterol levels, deposits of choles-
terol in peripheral tissues such as tendon xanthomas and accelerated atherosclerosis [2]. With
a heterozygous frequency prevalence as high as 1 in 200 in some populations [3, 4], FH is fre-
quently underdiagnosed [4, 5]. Most often, FH is caused by mutations in the Low Density
Lipoprotein Receptor gene (LDLR; MIM# 606945), which removes both Low-Density Lipo-
proteins (LDL) and Very Low Density Lipoproteins (VLDL) from the bloodstream [6].
Because FH patients usually respond well to medication, early diagnosis of FH can significantly
reduce the risk of CHD [7]. Genetic screening for LDLR pathogenic variants is a cost-effective
strategy to enable such early diagnoses [8]. As of August 31, 2018, a total of 2500 LDLR variants
have been identified in the ClinVar Database (https://clinvarminer.genetics.utah.edu). Since
this database includes pathogenic variants, non-pathogenic variants and variants with conflict-
ing interpretation, distinguishing pathogenic variants from non-pathogenic ones is a long-
standing challenge in the field [9].
The ability of LDL receptor (LDLr) to bind both LDL and VLDL is mediated by interactions
between the LDLr Ligand Binding Domain (LBD) and the apolipoprotein components of
VLDL and LDL [10]. While LDL is composed of a single copy of apolipoprotein (apo) B,
VLDL are heterogeneous particles that contains one copy of apo B and a variable number of
copies of the smaller apo E and/or apo CIII [11, 12], [13].
The LBD consists of seven cysteine-rich ligand-binding repeats (LRs) of approximately
40 residues each [14]. Each LR contains a single structural calcium ion [15] as well as six cys-
teines that interact via Cys(I)-Cys(III), Cys(II)-Cys(V) and Cys(IV)-Cys(VI) disulfide bonds
[16]. In each LR, the six cysteines surround a highly conserved negatively charged sequence
of Ser-Asp-Glu near the LR C-terminus [17]. This negatively charged sequence interacts
with positively charged residues on apo B and apo E to enable lipoprotein binding [18]. LR4
and LR5 play a mayor role in LDL particle recognition [10, 17], whereas deletion of individ-
ual repeats LR2–LR7 reduces LDL binding and, deletion of LR1 has little effect on lipopro-
tein binding [10, 17]. In addition, binding of VLDL or its remnants (β-VLDL) to LDL
receptor involves simultaneous binding of apo E copies to the LR5 along with additional
repeats of the LDLr[19]. Weak interactions between apo E and LR3, LR4 and LR5 have also
been described [20, 21].
The LR1 comprises 40 amino acids, which account for the 4.7% of the protein, whereas the
percentage of LR1 different missense variants found in the LDLR represent the 2.57% of the
missense described variants (ClinVar database). This percentage is in concordance with the
fact that the LR1 domain seems to be implicated to a lesser extent than LR2-LR7 in LDL and
VLDL binding. It is noteworthy that the cysteine missense variants represent the 42.3% of the
amino acid changes in LR1 reported in the ClinVar in relation to Hypercholesterolemia (actu-
alized August 31, 2018). Among them, mutations at Cys46, the fourth cysteine of the LR1
domain, have been described as pathogenic when the Cys is replaced by a Ser [22], while
replacement by a Gly or Tyr has not yet been functionally characterized [23, 24], unfortunately
none of them has been functionally characterized.
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In this study, in order to gain insight into the relevance of LR1 in LDL and VLDL binding
activity, we addressed the activity and affinity of LDLr with the substitution p.(Cys46Gly) to
LDL and VLDL. The selection of the p.(Cys46Gly) LDLr variant was based on three criteria:
our interest in studying mutations in LR1 region that could have a pathogenic effect (despite
this region has been considered no essential for LDLr activity[10, 17], previous documentation
of this variant in FH patients, and, obviously, to study a variant whose effect has not been char-
acterized before. Our results show that substitution of Cys46 by a Gly leads to a loss of LDLr
binding affinity for LDL leading to loss of binding and uptake, as determined by solid-phase
immunoassays and flow cytometry, respectively. In addition VLDL uptake results also
impaired as a consequence of p.(Cys46Gly) substitution. Our results highlight the role of LR1
in modulating the activity of LDLr and help in a better understanding of the potential mecha-
nisms of pathogenicity related to mutations in the LR1.
Materials and methods
In silico predictions of p.(Cys46Gly) LDLr variant activity
This variant has been included in the ClinVar database (https://clinvarminer.genetics.utah.
edu) by 3 submitters (accession code: RCV000238380) and has also been found in 3 FH index
cases by Progenika Biopharma (Derio, Spain). The in silico analysis of the selected variant is
compiled in Table 1.
Site-directed mutagenesis
Plasmid carrying the p.(Cys46Gly) LDLR variant was constructed by Innoprot (Derio, Spain).
Briefly, variants were introduced into the human LDLR cDNA (NM_000527.4), using the
mammalian expression vector pcDNA3 under control of a SV40 promoter by oligonucleotide
site-directed mutagenesis using the QuickChange Lightning mutagenesis kit (Agilent) accord-
ing to the manufacturer’s instructions. The oligonucleotides used to generate the plasmid car-
rying p.(Cys46Gly) LDLR variant were synthesized in vitro and subcloned using the restriction
enzymes SacII and EcoRI. The presence of the desired nucleotide alteration was confirmed by
PCR and restriction enzyme digestion of the appropriate fragments. The integrity of the
remaining LDLR cDNA sequence of the construct was verified by direct sequence analysis.
LDL receptor-ectodomain production and purification
The LDL receptor ectodomain (1–789 amino acids) plus c-myc and His tags in both wild type
(wt) and p.(Cys46Gly) LDLr variant were purified from cells transfected with the
pcDNA3.1-EC-LDLR-His plasmid, kindly provided by Prof. Leren [25] and pcDNA3.1-EC--
Cys46GlyLDLR-His plasmid, respectively. Briefly, HEK293 cells were transfected with the
plasmid by calcium phosphate method for 24–48 h and selected by geneticin (G-418 sulphate,
Gibco, Invitrogen). The LDLr ectodomain was affinity purified using one-step nickel affinity
chromatography as described before [26]. Cys46Gly variant was introduced by oligonucleotide
site-directed mutagenesis using QuickChange Lightning mutagenesis kit (Agilent) according
Table 1. Description of p.(Cys46Gly) LDLr variant, conservation and in silico predictions.
Genetic name HGVS Nomenclature Conservation nt Conservation AA
c.136T>G p.(Cys46Gly) 1.00 1.00
Pathogenicity prediction SIFT Align GVGD POLYPHEN-2 Mutation taster 2
Deleterious (score 0) Pathogenic (C0) Probably damaging (1) Disease causing (1.0)
https://doi.org/10.1371/journal.pone.0204771.t001
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to manufacturer’s instructions and using 5’-TAC AAG TGG GTC GGC GAT GGC AGC
GC-3’ and 5’-GCG CTG CCA TC GCC GAC CCA CTT GTA-3’ forward and reverse
primers, respectively.
Cell culture and transfection
LDLR-deficient CHO-ldlA7 cells (provided by Dr. Monty Krieger, Massachusetts Institute of
Technology, Cambridge, MA) were cultured in Ham’s F-12 medium containing 10% fetal
bovine serum (FBS), 2 mM L-glutamine (Invitrogen), 100 units/mL penicillin, and 100 μg/mL
streptomycin (Invitrogen). Transfections were carried out using Lipofectamine LTX and Plus
Reagent (Invitrogen) in 6- or 24-well culture plates according to the manufacturer’s instruc-
tions. The experiments were carried out 48 h post-transfection.
Western blot analysis
Cell lysates were prepared, using an ice-cold buffer containing 50 mM Tris–HCl, pH 7.5, 125
mM NaCl, 1% Nonidet P-40, 5.3 mM NaF, 1.5 mM NaP, 1 mM orthovanadate, 1 mg/ml prote-
ase inhibitor cocktail (Roche), and 0.25 mg/ml Pefabloc, 4-(2-aminoethyl)-benzenesulfonyl
fluoride hydrochloride (AEBSF; Roche). Cells were sonicated for 10 pulses at 10 kHz on ice,
rotated at 4˚C for an hour and centrifuged at 12,000g during 15 minutes to remove insoluble
material. Proteins were fractionated by electrophoresis on non-reducing 8.5% SDS-PAGE for
semi-quantitative immunoblotting. The following antibodies were added: rabbit polyclonal
anti-LDLr antibody (1:500) (Progen Biotechnik GmbH, Heidelberg, Germany), anti-Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) antibody (1:1000) (Nordic Biosite, Ta¨by, Swe-
den) and horseradish peroxidase-conjugated anti-rabbit antibody (GE Healthcare, Little
Chalfont, UK). The primary antibodies were incubated overnight at 4˚C while the secondary
antibody incubation was performed at room temperature for an hour. Signals were developed
using SuperSignal West Dura Extended Substrate (Pierce Biotechnology, Rockford, IL, USA)
in a ChemiDoc XRS (Bio-Rad, Hercules, CA, USA). NIH ImageJ software (http://rsbweb.nih.
gov/ij/) was used for band intensity quantification, levels of protein were corrected to GAPDH
loading control band intensities.
Lipoprotein isolation
Plasma used for lipoprotein purification was collected from healthy individuals blood after 30
min centrifugation, at 12,000 x g at 4˚C. The samples were then adjusted with KBr to d ¼
1.225 kg/L and a second PBS buffer phase was added in the top. The ultracentrifugation was
carried out in a TST SW-28ti (Beckman) at 27,000 rpm for 22 h at 4˚C in a Beckman Optima
L-90K. The white upper band corresponding to VLDL and the intermediate orange band cor-
responding to LDL were collected and stored at 4˚C. Isolated lipoproteins were used within
2–3 days after purification.
Solid-phase immunoassay for LDL-LDL receptor ectodomain binding
LDLr ectodomain fragments diluted in working buffer (10 mM Tris-HCl, pH 7.5, 50 mM
NaCl, 2 mM CaCl2) were coated at a fixed concentration onto 96-well microtiter plates by
incubation overnight at 4˚C. Plates were then blocked and incubated with a serial dilution of
LDL diluted in working buffer during 2 hours at room temperature, and then washed thor-
oughly with working buffer supplemented with 0.1% (w/v) Tween 20 (Sigma-Aldrich, MO,
USA). For ligand detection, the antibodies (goat polyclonal anti-apoB, abcam,UK; and peroxi-
dase-conjugated mouse anti-goat, ThermoScientific, USA) were diluted in working buffer
p.(Cys46Gly) LDLR variant diminishes LDL receptor activity
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supplemented with 5% (w/v) BSA, applied directly to the plate and incubated for 1 hour at
room temperature, with an extensive washing between both incubations. After a final wash,
antibody binding was determined using 50 μL per well of 2,2´-Azino-bis (3-ethylbenzothiazo-
line-6-sulfonic acid) substrate solution (Sigma-Aldrich, MO, USA) and measuring colour
change at 405 nm. The time course for colour development was essentially lineal and measure-
ments were taken 30–60 min after the addition of substrate. For data processing, all absor-
bance values were corrected for unspecific binding, relativized to maximum and EC50 values
were extracted from curves after fitting the data to 5-parameter logistic (5-PL) equation (Sig-
maPlot 13.0, Systat Software Inc., CA, USA).
Lipoprotein labelling
LDL and VLDL were labelled with FITC as previously described [27]. Briefly, lipoproteins
were loaded in a 0.1 M NaHCO3 (pH 9.0) pre-equilibrated Sephadex G-25 column and incu-
bated with 10 μl/mL FITC (2 mg/mL in dimethyl sulfoxide) per lipoprotein millilitre (1mg/
mL). The solution was mixed during 2 h at room temperature and then a Sephadex G-25 col-
umn was used to remove free FITC. Lipoprotein quantification was determined by Pierce
BCA protein assay.
LDLr expression determined by FACS
To determine LDLr cell surface expression by FACS the following antibodies were used:
mouse primary antibody anti-LDLr (1:100; 2.5 mg/L; Progen Biotechnik GmbH), rabbit pri-
mary anti-LDLr polyclonal antibody (1:100; Cayman Chemical), secondary antibody Alexa
Fluor 488-conjugated goat anti-mouse IgG (1:100; Molecular Probes) and Alexa Fluor
488-conjugated goat anti-rabbit IgG (1:100; Molecular Probes). The immunostaining was per-
formed as previously described [28]. Briefly, cells were incubated for 1 hour at room tempera-
ture with the primary antibody after consecutive fixing and blocking steps. Cells were finally
washed 3 times in PBS-1%BSA and incubated for 1 hour at room temperature with the second-
ary antibody. For each sample, fluorescence of 10,000 events was acquired for data analysis. All
measurements were performed at least in triplicate.
Quantification of LDLr activity by flow cytometry
Cells were seeded in 24-well plates, at 106 cells/well and transfected as previously described
when optimal concentration was reached. 48 hours after transfection, cells were incubated
with 20 μg/mL FITC-LDL or FITC-VLDL within 4 hours at 37˚C or at 4˚C to determine LDLr
activity and its binding to the different lipoproteins respectively. After incubation, cells were
washed three times with PBS-1%BSA, fixed for 10 minutes in 4% paraformaldehyde and
washed again to remove the remaining fixative.
FITC-LDL or FITC-VLDL uptake was determined by adding Trypan blue solution 0.2%
final concentration (Sigma-Aldrich, Steinheim, Germany) to the samples thus quenching the
extracellular fluorescence of the non-internalized lipoproteins. Fluorescence acquisition was
performed in a FACScalibur Flow cytometer as previously described [29]. For each determina-
tion, at least 10,000 events were acquired and analysed with the CellQuest software system
(Beckton and Dickinson).
Statistical analysis
All measurements were performed at least 3 times, with at least 3 independent determinations
for each measurement. Results shown in Table 2 and figures represent mean ± standard error
p.(Cys46Gly) LDLR variant diminishes LDL receptor activity
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of mean (S.D). A two-tailed Student’s t-test was used to determine levels of significance.. p-val-
ues lesser than or equal to 0.05 were considered significant.
Results
In silico functional predictions of p.(Cys46Gly) LDLr variant
Four software programs were used to predict pathogenicity of p.(Cys46Gly) LDLr variant. As
shown in Table 1. p.(Cys46Gly) variant was predicted as pathogenic by SIFT, GVGD and
Mutation taster2 programs and as probably damaging by Polyphen-2. Because the prediction
algorithms are mainly based on amino acid conservation analysis and Cys46 is highly con-
served, the obtained predictions were the expected ones. To confirm these predictions, in vitro
functional validation of LDLr variant was next assayed.
Expression of LDLr variants in CHO-ldlA7 cells
Expression of p.(Cys46Gly) LDLr variant was analysed by Western blot in CHO-ldlA7 trans-
fected cells as described in Materials and Methods. LDLr signal (Fig 1A, upper panel) was nor-
malized with GAPDH levels (Fig 1A, lower panel) and LDLr expression levels were quantified
by densitometry (Fig 1B). Accordingly, p.(Cys46Gly) LDLr variant is expressed at similar levels
as wt 48 h after transfection. Ex3_4del LDLr variant that produces a binding-defective LDLr
was used as internal controls [10]. These results were also corroborated by determining LDLr
expression by flow cytometry. Using both a IgG-C7 antibody recognizing the N-terminal
ligand binding repeat of the LDLr and a polyclonal anti-LDLr antibody, we found that LDLr
expression of p.(Cys45Gly) was similar to wt (Fig 1C and 1D, respectively).
Affinity of wt LDLr and p.(Cys46Gly) LDLr variant for LDL
Next, we tested binding affinities of wt and p.(Cys46Gly) LDLr for LDL using a solid-phase
binding immunoassay. The EC50 for wt LDLr to LDL was calculated to be 0.58 ± 0.11 nM, very
similar to previously reported values[30, 31]. Consistently with the results obtained by flow
cytometry, the p.(Cys46Gly) LDLr variant showed a significant lower affinity for LDL
(15.79 ± 2.05 nM, p<0.01) (Table 2). Binding affinities of LDL-LDLr and LDL- p.(Cys46Gly)
LDLr variant were also determined at pH 5.2, as expected wt LDLr showed a lower affinity for
LDL at acidic pH with a Kd = 7.01 ± 2.02 nM. Interestingly, p.(Cys46Gly) LDLr showed a
higher affinity to LDL (4.15 ± 0.86 nM, p<0.01) at pH 5.2.
Analysis of LDLr activity in CHO-ldlA7 cells
CHO-ldlA7 cells expressing wt or p.(Cys46Gly) LDLr variant were assayed for LDL binding and
uptake by flow cytometry. Two internal controls were used: p.(Trp87) (a null allele mutant),
Table 2. LDL affinity for wild type and p.(Cys46Gly) LDLr variant.
LDL-LDLr ectodomain dissociation constant (KD) pH 7.4
Kd (nM) S.D
wt 0.58 0.11
p.(Cys46Gly) 15.79 2.05
LDL-LDLr ectodomain dissociation constant (KD) pH 5.2
Kd (nM) S.D
wt 7.01 2.02
p.(Cys46Gly) 4.15 0.86
https://doi.org/10.1371/journal.pone.0204771.t002
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and Ex3_4del LDLR variant that produces a binding-defective LDL receptor [10]. As shown in
Fig 2A, LDL- LDLr binding activity of p.(Cys46Gly) variant resulted in 35% lower compared to
wt LDLr (100 ± 3 vs. 65 ± 8, p<0.01) (Fig 2A). As shown in Fig 2B and in agreement with LDLr
binding results, LDL internalisation in cells expressing p.(Cys46Gly) variant was significantly
diminished ( 40% reduction, 100 ± 4 vs. 60 ± 2, p<0.01) when compared to wt.
VLDL (E3/E3) uptake in CHO-ldlA7 cells
CHO-ldlA7 cells transfected with wt or p.(Cys46Gly) LDLr variant were used to determine if
the amino acid substitution impairs apoE3 VLDL uptake activity. In this assay, Ex3_4del
mutant was also used as an internal control because it lacks the LR4 module, which, together
with LR5, is required for VLDL binding. As shown in Fig 3, VLDL uptake in p.(Cys46Gly)
LDLr variant was significantly decreased ( 45% reduction, 100 ± 2 vs. 55 ± 7, p<0.01) when
compared to wt, (Fig 3).
Discussion
This study has been focused on the p.(Cys46Gly) LDLr variant, previously associated with FH
but not functionally characterized [23]. Despite being classified as pathogenic in the ClinVar
Fig 1. Expression of wt LDLr and p.(Cys46Gly) LDLr variant in CHO-ldlA7 transfected cells. Expression of LDLr was assessed 48 h post-transfection
with the corresponding plasmids by A) Western blot, B) mature LDLr protein relative to GAPDH. LDLr expression of p.(Cys46Gly) LDLr variant
determined by FACS with C) IgG-C7 antibody that recognizes the N-terminal ligand binding repeat of the LDLr and D) a polyclonal anti- LDLr antibody. A
representative blot is shown in panel A. The values in C and D represent the mean of triplicate determinations (n = 3); error bars represent ±SD. P< 0.001
compared to wt using a Student’s t-test.
https://doi.org/10.1371/journal.pone.0204771.g001
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database (https://clinvarminer.genetics.utah.edu) by two of the 3 submitters, all prior classifi-
cation criteria was based only on predictions. In order to gain insight into the role of LR1 in
LDLr activity we experimentally determined in vitro the functionality of p.(Cys46Gly) LDLr
variant. The data obtained by solid-phase immunoassays and FACS show that replacement of
Fig 2. LDLr activity of wt and p.(Cys46Gly) LDLr variants. A) LDL- LDLr binding and B) FITC-LDL uptake activity.
Assays were performed as described in Materials and Methods. Data show the mean of three independent experiments;
error bars represent ±SD. P< 0.001 compared to wt using a Student’s t-test.
https://doi.org/10.1371/journal.pone.0204771.g002
p.(Cys46Gly) LDLR variant diminishes LDL receptor activity
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Cys46 by a glycine diminishes the affinity for both LDL and VLDL thus negatively modulating
LDLr activity, emphasising the role of LR1 on LDLr activity.
The binding domain of LDLr to lipoproteins is organized into seven cysteine rich domains
called LR1-LR7 [32], each of which is composed of about 40 amino acids and stabilized by
three disulphide bridges [16]. The coordination of each LR with one Ca2+ ion facilitates LR
folding in a way that makes the mature LR capable of lipoprotein binding [33].
In particular, the role of LR1 in binding lipoproteins has been highly controversial. Deletion
of the whole LR1 from LDLr affects neither LDL nor VLDL binding [10, 17]. Consistent with
this, truncated proteins containing only LR1 are unable to bind any lipoprotein [34]. These
findings initially led to the erroneous conclusion that LR1 is not involved in lipoprotein bind-
ing [34]. Later studies, however, found that lipoprotein binding is more likely coordinated by a
combination of multiple LRs including LR1 [34]. While deletion of the whole LR1 does not
alter lipoprotein binding, missense mutations in LR1 can significantly alter lipoprotein bind-
ing[34]. The number of variants located at LR1 is lower than the number found at LR2-LR7,
26 variants compared to 50–72, according to ClinVar database. Among these 26 missense vari-
ants, 11 are classified as pathogenic by at least 1 submitter but only the ones impairing a Cys
have been really demonstrated to be pathogenic by a functional study, the rest of them have
not enough data to support their classification as pathogenic. This finding at least suggests that
substitutions at the cysteine residues of the LR1 can be responsible for reduced LDLr activity
leading concomitantly to FH.
Specifically, in the case of p.(Cys46Gly) LDLr variant, substitution of a cysteine by glycine
can disturb the structure of LR1, since loss of the CysIV-CysVI disulphide bridge can lead to
several disulphide-bonded isomers. Because the cysteine amino acid plays a key role in main-
taining integrity of the binding subunits, replacement by other amino acid would allow neither
proper folding of the LR nor calcium coordination[35, 36] as previously demonstrated in cys-
teine substitutions in LDLr located in the LBD [35, 37]. Our findings here, however, show that
the IgG-C7 antibody, which recognizes a structural epitope at the N-terminus of LR1, is still
Fig 3. Analysis of VLDL uptake in wt and p.(Cys46Gly) LDLr variant. VLDL uptake activity. Assays were performed
as described in Materials and Methods using FITC-labelled VLDL. Data show the mean of three independent
experiments; error bars represent ±SD. P< 0.001 compared to wt using a Student’s t-test.
https://doi.org/10.1371/journal.pone.0204771.g003
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able to bind the receptor. This would indicate that this epitope in LR1 is still intact, and for this
reason, we suggest that the substitution of Cys at position 46 by Gly does not completely desta-
bilize the LR1 structure. Moreover, expression of p.(Cys46Gly) LDLr variant is similar to that
of wt LDLr indicating a minimal contribution of other disulphide-bonded isomers that proba-
bly are retained in the endolasmic reticulum and ultimately degraded [38].
Taking together that the first binding repeat is not essential for LDL recognition [39]
and that the integrity of the first repeat is at least not dramatically affected, it could be
expected that the p.(Cys46Gly) LDLr variant would not affect the activity of LDLr. Never-
theless, the diminished LDLr activity demonstrated by our experimental data suggests that
the cysteine at position 46 itself plays an active role in receptor activity. Several amino acid
substitutions by glycines lead to an increased elasticity and mobility of the proteins because
of the short side chain of the glycines. These changes allow positional variations of the resi-
dues within the protein, even without a significant change in R1 folding. This in turn, could
slightly modify the structure of the contiguous binding repeats and contribute to a loss of
LDL binding activity [10].
In summary, we found that the p.(Cys46Gly) LDLr variant has a diminished LDL and
VLDL binding activity, as assessed by solid-phase immunoassay and FACS using CHO-
ldlA7 cells. Because the used experimental models mimic the presence of the variant at
homozygous status, the 40–45% of activity reduction in the p.(Cys46Gly) LDLr variant indi-
cates the variant is mildly pathogenic. This is especially relevant because LDLR mutations
with similar effects in heterozygous state could go unnoticed due to masking by the wildtype
LDLR allele. In addition, the different severity of the mutations can explain the high variabil-
ity found in the FH phenotype. Our findings here reinforce that in vitro functional charac-
terization of LDLr variants is a gold standard in genetic diagnosis of Familial
Hypercholesterolemia, particularly when the LDLr activity is only partially reduced, as is the
case of the p.(Cys46Gly) variant.
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